Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Sildenafil Treatment Less Effective in Men With Diabetes Than in Non-Diabetics

        A DGReview of :"Oral sildenafil in the treatment of erectile dysfunction in diabetic men; A randomized double-blind and placebo-controlled study"
        Journal of Diabetes and its Complications

        07/09/2004
        By Shane Alexander


        Oral sildenafil is only moderately effective in the treatment of erectile dysfunction in patients with diabetes, an Iranian researcher reports.

        "The response rate was lower and cardiovascular events were higher than previously reported in nondiabetic patients," writes M. R. Safarinejad, MD, Department of Urology, Military University of Medical Sciences, Tehran.

        A total of 282 men (mean age 46.4 years) with erectile dysfunction (mean duration 3.6 years) and diabetes (mean duration 11 years) were recruited for this randomised, double-blind, placebo-controlled trial.

        Over the 16-week study period, 144 men were assigned to receive sildenafil 100 mg approximately 1 hour before sexual activity and 138 men received a matching placebo.

        Treatment efficacy was evaluated using the International Index of Erectile Function questionnaire. Ninety-three percent of men in the sildenafil group and 93% of men in the placebo group completed the study.

        The investigator reports positive clinical results in 51% of men in the sildenafil group compared with 11% of men in the placebo group (P < .003). In the sildenafil group, 59% of men noted at least 1 successful attempt at sexual intercourse compared with 21% of men in the placebo group (P < .002).

        Adverse effects were reported by 22 % of men treated with sildenafil compared with 3 % of men in the placebo group. The most frequently reported adverse events were: headaches (sildenafil: 20%, placebo: 2%), flushing (sildenafil: 19%, placebo: 0%), rhinitis (sildenafil: 6%, placebo: 0%), and cardiovascular events (sildenafil: 7%, placebo: 0%).

        Two percent of patients treated with sildenafil reported new chest pain; myocardial infarction was documented in half of those patients.

        J Diabetes Complications 2004 Jul-Aug;18:4:205-10 "Oral sildenafil in the treatment of erectile dysfunction in diabetic men; A randomized double-blind and placebo-controlled study"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send